Tags

Type your tag names separated by a space and hit enter

Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy.
Rom J Intern Med 1999 Jul-Sep; 37(3):297-306RJ

Abstract

Alpha lipoic acid is a natural antioxidant that has been suggested to improve symptoms of diabetic neuropathy. To assess these potential benefits, a cohort of 26 type 2 diabetic patients with symptomatic peripheral neuropathy (stage 2) received a daily dose of 600 mg alpha-lipoic acid, and were followed for a 3 month-period. No dropout was noted. At the end of the follow-up period, in 20 subjects (76.9%) there was a 1-stage regression of somatic neuropathy (from symptomatic to asymptomatic neuropathy, and in 5 patients (19.2%) no signs of neuropathy were found. The nerve conduction velocity of motor fibers improved from 36.8 (95% Confidence Interval CI = 30.9-42.7) meters/second to 41.3 (95% CI = 39.5-43.0) meters/second (p = 0.049, paired t test). Mean blood glucose measured was significantly lower at 3 months than at baseline [197.9 (95% CI = 170.1-225.7) versus 162.2 (95% CI = 146.1-178.2 mg/dl, p = 0.02, paired t test)]. In a multiple linear regression model with age. sex, body mass index, diabetes duration and the difference between blood glucose values at 3 months and at baseline as explanatory variables, the increment in nerve conduction velocity was not accounted for by the improved glycemic control. Women, thinner and younger patients tended to benefit more from the treatment in terms of nervous conduction velocity improvement. In conclusion, alpha-lipoic acid seems to be efficient and safe in the treatment of diabetic peripheral neuropathy, improving both clinical manifestations and nerve conduction velocity. Placebo controlled clinical trials are needed to further define the role of this new medication in the treatment of diabetic neuropathies.

Authors+Show Affiliations

Department of Diabetes, University of Medicine, Timişoara.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

15532308

Citation

Negrişanu, G, et al. "Effects of 3-month Treatment With the Antioxidant Alpha-lipoic Acid in Diabetic Peripheral Neuropathy." Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, vol. 37, no. 3, 1999, pp. 297-306.
Negrişanu G, Roşu M, Bolte B, et al. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. Rom J Intern Med. 1999;37(3):297-306.
Negrişanu, G., Roşu, M., Bolte, B., Lefter, D., & Dabelea, D. (1999). Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 37(3), pp. 297-306.
Negrişanu G, et al. Effects of 3-month Treatment With the Antioxidant Alpha-lipoic Acid in Diabetic Peripheral Neuropathy. Rom J Intern Med. 1999;37(3):297-306. PubMed PMID: 15532308.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. AU - Negrişanu,G, AU - Roşu,M, AU - Bolte,B, AU - Lefter,D, AU - Dabelea,D, PY - 2004/11/10/pubmed PY - 2004/12/16/medline PY - 2004/11/10/entrez SP - 297 EP - 306 JF - Romanian journal of internal medicine = Revue roumaine de medecine interne JO - Rom J Intern Med VL - 37 IS - 3 N2 - Alpha lipoic acid is a natural antioxidant that has been suggested to improve symptoms of diabetic neuropathy. To assess these potential benefits, a cohort of 26 type 2 diabetic patients with symptomatic peripheral neuropathy (stage 2) received a daily dose of 600 mg alpha-lipoic acid, and were followed for a 3 month-period. No dropout was noted. At the end of the follow-up period, in 20 subjects (76.9%) there was a 1-stage regression of somatic neuropathy (from symptomatic to asymptomatic neuropathy, and in 5 patients (19.2%) no signs of neuropathy were found. The nerve conduction velocity of motor fibers improved from 36.8 (95% Confidence Interval CI = 30.9-42.7) meters/second to 41.3 (95% CI = 39.5-43.0) meters/second (p = 0.049, paired t test). Mean blood glucose measured was significantly lower at 3 months than at baseline [197.9 (95% CI = 170.1-225.7) versus 162.2 (95% CI = 146.1-178.2 mg/dl, p = 0.02, paired t test)]. In a multiple linear regression model with age. sex, body mass index, diabetes duration and the difference between blood glucose values at 3 months and at baseline as explanatory variables, the increment in nerve conduction velocity was not accounted for by the improved glycemic control. Women, thinner and younger patients tended to benefit more from the treatment in terms of nervous conduction velocity improvement. In conclusion, alpha-lipoic acid seems to be efficient and safe in the treatment of diabetic peripheral neuropathy, improving both clinical manifestations and nerve conduction velocity. Placebo controlled clinical trials are needed to further define the role of this new medication in the treatment of diabetic neuropathies. SN - 1220-4749 UR - https://www.unboundmedicine.com/medline/citation/15532308/Effects_of_3_month_treatment_with_the_antioxidant_alpha_lipoic_acid_in_diabetic_peripheral_neuropathy_ L2 - https://medlineplus.gov/diabeticnerveproblems.html DB - PRIME DP - Unbound Medicine ER -